| # | Title | Journal | Year | Citations |
|---|
| 1 | Eradication of Helicobacter pylori Using One-week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study | Helicobacter | 1996 | 562 |
| 2 | Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition | Helicobacter | 2010 | 416 |
| 3 | Epidemiology of Helicobacter pylori Infection | Helicobacter | 2014 | 412 |
| 4 | A Report Card to Grade Helicobacter pylori Therapy | Helicobacter | 2007 | 327 |
| 5 | Epidemiology of Helicobacter pylori infection | Helicobacter | 2016 | 321 |
| 6 | Epidemiology of Helicobacter pylori Infection | Helicobacter | 2007 | 316 |
| 7 | Epidemiology of Helicobacter pylori Infection and Public Health Implications | Helicobacter | 2011 | 316 |
| 8 | Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection | Helicobacter | 2018 | 304 |
| 9 | Treatment of Helicobacter pylori Infection: A Review of the World Literature | Helicobacter | 1996 | 295 |
| 10 | Differences in Gastric Mucosal Microbiota Profiling in Patients with Chronic Gastritis, Intestinal Metaplasia, and Gastric Cancer Using Pyrosequencing Methods | Helicobacter | 2014 | 253 |
| 11 | Seroprevalence of Helicobacter pylori in South Korea | Helicobacter | 2007 | 251 |
| 12 | Epidemiology and Diagnosis of Helicobacter pylori infection | Helicobacter | 2015 | 229 |
| 13 | Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012 | Helicobacter | 2013 | 214 |
| 14 | Meta‐analysis: Four‐Drug, Three‐Antibiotic, Non‐bismuth‐Containing “Concomitant Therapy” Versus Triple Therapy for Helicobacter pylori Eradication | Helicobacter | 2009 | 209 |
| 15 | Low Prevalence of Helicobacter pylori-negative Gastric Cancer among Japanese | Helicobacter | 2011 | 205 |
| 16 | Randomized Placebo‐Controlled Trial ofHelicobacter pylori Eradication for Iron‐Deficiency Anemia in Preadolescent Children and Adolescents | Helicobacter | 1999 | 203 |
| 17 | The Versatility of Helicobacter pylori CagA Effector Protein Functions: The Master Key Hypothesis | Helicobacter | 2010 | 202 |
| 18 | Epidemiology of Helicobacter pylori Infection | Helicobacter | 2004 | 201 |
| 19 | The Long‐term Impact of Helicobacter pylori Eradication on Gastric Histology: a Systematic Review and Meta‐analysis | Helicobacter | 2007 | 201 |
| 20 | Atrophic Gastritis and Intestinal Metaplasia in Japan: Results of a Large Multicenter Study | Helicobacter | 2001 | 197 |
| 21 | Pathogenesis of Helicobacter pylori infection | Helicobacter | 2017 | 196 |
| 22 | Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition | Helicobacter | 2019 | 189 |
| 23 | Helicobacter pylori Infection and Iron Stores: A Systematic Review and Meta‐analysis | Helicobacter | 2008 | 179 |
| 24 | Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review | Helicobacter | 2004 | 176 |
| 25 | The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review | Helicobacter | 2011 | 175 |
| 26 | Epidemiology of Helicobacter pylori Infection | Helicobacter | 2008 | 170 |
| 27 | Antimicrobial Activity of Essential Oils against Helicobacter pylori | Helicobacter | 2003 | 166 |
| 28 | H. pyloriandcagA: Relationships with Gastric Cancer, Duodenal Ulcer, and Reflux Esophagitis and Its Complications | Helicobacter | 1998 | 164 |
| 29 | Relationship ofvacAGenotypes ofHelicobacter pyloritocagAStatus, Cytotoxin Production, and Clinical Outcome | Helicobacter | 1998 | 163 |
| 30 | Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days | Helicobacter | 2011 | 160 |
| 31 | Epidemiology of Helicobacter pylori infection | Helicobacter | 2017 | 158 |
| 32 | Extragastric Diseases and Helicobacter pylori | Helicobacter | 2015 | 150 |
| 33 | Pathogenesis of Helicobacter pylori infection | Helicobacter | 2016 | 147 |
| 34 | A Multicenter, Double-Blind Study on Triple Therapy with Lansoprazole, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori in Japanese Peptic Ulcer Patients | Helicobacter | 2001 | 146 |
| 35 | Epidemiology of Helicobacter pylori infection and Public Health Implications | Helicobacter | 2010 | 146 |
| 36 | Association Between Common Genetic Variants in Pre‐microRNAs and Gastric Cancer Risk in Japanese Population | Helicobacter | 2010 | 142 |
| 37 | Evolution of Helicobacter pylori Research as Observed Through the Workshops of the European Helicobacter Study Group | Helicobacter | 2007 | 138 |
| 38 | Antibiotic Resistance of Helicobacter Pylori Isolated in the Southeast Coastal Region of China | Helicobacter | 2013 | 136 |
| 39 | Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study | Helicobacter | 2008 | 135 |
| 40 | Prevalence of Helicobacter pylori Resistance to Metronidazole, Clarithromycin, Amoxicillin, Tetracycline, and Furazolidone in Brazil | Helicobacter | 2000 | 134 |
| 41 | Disease-specific Helicobacter pylori Virulence Factors: The Unfulfilled Promise | Helicobacter | 2000 | 129 |
| 42 | Effect of Helicobacter pylori Eradication on Metachronous Gastric Cancer after Endoscopic Resection of Gastric Tumors: A Meta‐Analysis | Helicobacter | 2014 | 128 |
| 43 | Helicobacter pylori-Related Iron Deficiency Anemia: A Review | Helicobacter | 2002 | 127 |
| 44 | Extragastric Manifestations of Helicobacter pylori Infection | Helicobacter | 2012 | 127 |
| 45 | Survival of Helicobacter pylori in gastric acidic territory | Helicobacter | 2017 | 127 |
| 46 | Prevalence and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in a Korean Population Without Significant Gastroduodenal Disease | Helicobacter | 2008 | 126 |
| 47 | Treatment of Helicobacter pylori | Helicobacter | 2007 | 125 |
| 48 | Epidemiology of Helicobacter pylori Infection | Helicobacter | 2006 | 124 |
| 49 | Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple Therapy | Helicobacter | 2007 | 124 |
| 50 | Efficacy and Safety of Saccharomyces boulardii in the 14-day Triple Anti-Helicobacter pylori Therapy: A Prospective Randomized Placebo-Controlled Double-Blind Study | Helicobacter | 2007 | 124 |
